Logo

Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

Share this

Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

Shots:

  • Ribometrix to get $20M up front including an equity investment in the company with $700M as development- regulatory and commercial milestones and royalties on sales on any product. Vertex to discover two programs in collaboration with Ribometrix and has an option to add the third program & to take exclusive WW license for the development and commercialization of molecules for that program
  • The collaboration will combine Ribometrix’s discovery platform with Vertex’s clinical and regulatory capabilities for up to three therapeutic programs- including one ongoing discovery program from Ribometrix
  • Ribometrix RNA-targeted therapeutics platform used for identifying and optimizing small molecule therapeutics- modulating the RNA function by targeting 3D RNA structure

Click here to­ read full press release/ article 

 Ref: Businesswire | Image: Vertex


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions